Akihiro Seki
Appearances
- DateMay 19, 2024Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…
Presenter
Speakers
University Hospitals LeuvenIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai
